QLS1410 in Participants With Uncontrolled Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 260 participants.
Also called NCT07489612
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 260 participants
- Registry
-
NCT07489612
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT07489612. Randomized; quadruple masking; primary purpose treatment. Start 2026-04 (anticipated); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- QLS1410 in Participants With Uncontrolled Hypertension
- Condition
- Hypertension (HTN)
- Intervention (Drug)
- Dose 1 of QLS1410
- Intervention (Drug)
- Dose 2 of QLS1410
- Intervention (Drug)
- Dose 3 of QLS1410
- Intervention (Drug)
- placebo
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07489612- Content hash
ce20064385d4b8947e381d5d4368b6401f61a3ee1f8eb3f973f154cadab25b18